1
|
Garcia-Leon MJ, Liboni C, Mittelheisser V, Bochler L, Follain G, Mouriaux C, Busnelli I, Larnicol A, Colin F, Peralta M, Osmani N, Gensbittel V, Bourdon C, Samaniego R, Pichot A, Paul N, Molitor A, Carapito R, Jandrot-Perrus M, Lefebvre O, Mangin PH, Goetz JG. Platelets favor the outgrowth of established metastases. Nat Commun 2024; 15:3297. [PMID: 38740748 DOI: 10.1038/s41467-024-47516-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Accepted: 03/26/2024] [Indexed: 05/16/2024] Open
Abstract
Despite abundant evidence demonstrating that platelets foster metastasis, anti-platelet agents have low therapeutic potential due to the risk of hemorrhages. In addition, whether platelets can regulate metastasis at the late stages of the disease remains unknown. In this study, we subject syngeneic models of metastasis to various thrombocytopenic regimes to show that platelets provide a biphasic contribution to metastasis. While potent intravascular binding of platelets to tumor cells efficiently promotes metastasis, platelets further support the outgrowth of established metastases via immune suppression. Genetic depletion and pharmacological targeting of the glycoprotein VI (GPVI) platelet-specific receptor in humanized mouse models efficiently reduce the growth of established metastases, independently of active platelet binding to tumor cells in the bloodstream. Our study demonstrates therapeutic efficacy when targeting animals bearing growing metastases. It further identifies GPVI as a molecular target whose inhibition can impair metastasis without inducing collateral hemostatic perturbations.
Collapse
Affiliation(s)
- Maria J Garcia-Leon
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France.
- Université de Strasbourg, Strasbourg, France.
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.
- Equipe Labellisée Ligue Contre le Cancer, Paris, France.
- Domain therapeutics, Parc d'Innovation - 220 Boulevard Gonthier D'Andernach, 67400, Strasbourg - Illkirch, France.
| | - Cristina Liboni
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Vincent Mittelheisser
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Louis Bochler
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Gautier Follain
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
| | - Clarisse Mouriaux
- UMR_S 1255, INSERM, Etablissement Français du Sang-Alsace, Université de Strasbourg, F-67000, Strasbourg, France
| | - Ignacio Busnelli
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Annabel Larnicol
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Florent Colin
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Marina Peralta
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Naël Osmani
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Valentin Gensbittel
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Catherine Bourdon
- UMR_S 1255, INSERM, Etablissement Français du Sang-Alsace, Université de Strasbourg, F-67000, Strasbourg, France
| | - Rafael Samaniego
- Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Unidad de Microscopía Confocal, Madrid, Spain
| | - Angélique Pichot
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Laboratoire d'ImmunoRhumatologie Moléculaire, Plateforme GENOMAX, Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg Transplantex NG, Faculté de Médecine, France
| | - Nicodème Paul
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Laboratoire d'ImmunoRhumatologie Moléculaire, Plateforme GENOMAX, Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg Transplantex NG, Faculté de Médecine, France
| | - Anne Molitor
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Laboratoire d'ImmunoRhumatologie Moléculaire, Plateforme GENOMAX, Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg Transplantex NG, Faculté de Médecine, France
| | - Raphaël Carapito
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Laboratoire d'ImmunoRhumatologie Moléculaire, Plateforme GENOMAX, Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg Transplantex NG, Faculté de Médecine, France
- Service d'Immunologie Biologique, Plateau Technique de Biologie, Pôle de Biologie, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, 1 Place de l'Hôpital, 67091, Strasbourg, France
| | | | - Olivier Lefebvre
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Pierre H Mangin
- UMR_S 1255, INSERM, Etablissement Français du Sang-Alsace, Université de Strasbourg, F-67000, Strasbourg, France.
| | - Jacky G Goetz
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France.
- Université de Strasbourg, Strasbourg, France.
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.
- Equipe Labellisée Ligue Contre le Cancer, Paris, France.
| |
Collapse
|
2
|
Mittelheisser V, Gensbittel V, Bonati L, Li W, Tang L, Goetz JG. Evidence and therapeutic implications of biomechanically regulated immunosurveillance in cancer and other diseases. Nat Nanotechnol 2024; 19:281-297. [PMID: 38286876 DOI: 10.1038/s41565-023-01535-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 09/26/2023] [Indexed: 01/31/2024]
Abstract
Disease progression is usually accompanied by changes in the biochemical composition of cells and tissues and their biophysical properties. For instance, hallmarks of cancer include the stiffening of tissues caused by extracellular matrix remodelling and the softening of individual cancer cells. In this context, accumulating evidence has shown that immune cells sense and respond to mechanical signals from the environment. However, the mechanisms regulating these mechanical aspects of immune surveillance remain partially understood. The growing appreciation for the 'mechano-immunology' field has urged researchers to investigate how immune cells sense and respond to mechanical cues in various disease settings, paving the way for the development of novel engineering strategies that aim at mechanically modulating and potentiating immune cells for enhanced immunotherapies. Recent pioneer developments in this direction have laid the foundations for leveraging 'mechanical immunoengineering' strategies to treat various diseases. This Review first outlines the mechanical changes occurring during pathological progression in several diseases, including cancer, fibrosis and infection. We next highlight the mechanosensitive nature of immune cells and how mechanical forces govern the immune responses in different diseases. Finally, we discuss how targeting the biomechanical features of the disease milieu and immune cells is a promising strategy for manipulating therapeutic outcomes.
Collapse
Affiliation(s)
- Vincent Mittelheisser
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Strasbourg, France
| | - Valentin Gensbittel
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France
- Université de Strasbourg, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Strasbourg, France
| | - Lucia Bonati
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Weilin Li
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Li Tang
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
- Institute of Materials Science and Engineering, EPFL, Lausanne, Switzerland.
| | - Jacky G Goetz
- Tumor Biomechanics, INSERM UMR_S1109, Strasbourg, France.
- Université de Strasbourg, Strasbourg, France.
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.
- Equipe Labellisée Ligue Contre le Cancer, Strasbourg, France.
| |
Collapse
|
3
|
Colin F, Gensbittel V, Goetz JG. Biomechanics: a driving force behind metastatic progression. C R Biol 2021; 344:249-262. [DOI: 10.5802/crbiol.62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Accepted: 10/04/2021] [Indexed: 11/24/2022]
|
4
|
Follain G, Osmani N, Gensbittel V, Asokan N, Larnicol A, Mercier L, Garcia-Leon MJ, Busnelli I, Pichot A, Paul N, Carapito R, Bahram S, Lefebvre O, Goetz JG. Author Correction: Impairing flow-mediated endothelial remodeling reduces extravasation of tumor cells. Sci Rep 2021; 11:17765. [PMID: 34471187 PMCID: PMC8410853 DOI: 10.1038/s41598-021-97172-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Gautier Follain
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.,Université de Strasbourg, 67000, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France.,Turku Bioscience Center, University of Turku, Åbo Akademi University, 20520, Turku, Finland
| | - Naël Osmani
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.,Université de Strasbourg, 67000, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Valentin Gensbittel
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.,Université de Strasbourg, 67000, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Nandini Asokan
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.,Université de Strasbourg, 67000, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Annabel Larnicol
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.,Université de Strasbourg, 67000, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Luc Mercier
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.,Université de Strasbourg, 67000, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France.,UMR 5297, Interdisciplinary Institute for Neurosciences, CNRS Université de Bordeaux, 33076, Bordeaux, France
| | - Maria Jesus Garcia-Leon
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.,Université de Strasbourg, 67000, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Ignacio Busnelli
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.,Université de Strasbourg, 67000, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Angelique Pichot
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.,Université de Strasbourg, 67000, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
| | - Nicodème Paul
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.,Université de Strasbourg, 67000, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
| | - Raphaël Carapito
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.,Université de Strasbourg, 67000, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
| | - Seiamak Bahram
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.,Université de Strasbourg, 67000, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
| | - Olivier Lefebvre
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France. .,Université de Strasbourg, 67000, Strasbourg, France. .,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France. .,Equipe Labellisée Ligue Contre le Cancer, Paris, France.
| | - Jacky G Goetz
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France. .,Université de Strasbourg, 67000, Strasbourg, France. .,Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France. .,Equipe Labellisée Ligue Contre le Cancer, Paris, France.
| |
Collapse
|
5
|
Follain G, Osmani N, Gensbittel V, Asokan N, Larnicol A, Mercier L, Garcia-Leon MJ, Busnelli I, Pichot A, Paul N, Carapito R, Bahram S, Lefebvre O, Goetz JG. Impairing flow-mediated endothelial remodeling reduces extravasation of tumor cells. Sci Rep 2021; 11:13144. [PMID: 34162963 PMCID: PMC8222393 DOI: 10.1038/s41598-021-92515-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Accepted: 05/31/2021] [Indexed: 01/02/2023] Open
Abstract
Tumor progression and metastatic dissemination are driven by cell-intrinsic and biomechanical cues that favor the growth of life-threatening secondary tumors. We recently identified pro-metastatic vascular regions with blood flow profiles that are permissive for the arrest of circulating tumor cells. We have further established that such flow profiles also control endothelial remodeling, which favors extravasation of arrested CTCs. Yet, how shear forces control endothelial remodeling is unknown. In the present work, we aimed at dissecting the cellular and molecular mechanisms driving blood flow-dependent endothelial remodeling. Transcriptomic analysis of endothelial cells revealed that blood flow enhanced VEGFR signaling, among others. Using a combination of in vitro microfluidics and intravital imaging in zebrafish embryos, we now demonstrate that the early flow-driven endothelial response can be prevented upon specific inhibition of VEGFR tyrosine kinase and subsequent signaling. Inhibitory targeting of VEGFRs reduced endothelial remodeling and subsequent metastatic extravasation. These results confirm the importance of VEGFR-dependent endothelial remodeling as a driving force of CTC extravasation and metastatic dissemination. Furthermore, the present work suggests that therapies targeting endothelial remodeling might be a relevant clinical strategy in order to impede metastatic progression.
Collapse
Affiliation(s)
- Gautier Follain
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
- Turku Bioscience Center,, University of Turku, Åbo Akademi University, 20520, Turku, Finland
| | - Naël Osmani
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Valentin Gensbittel
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Nandini Asokan
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Annabel Larnicol
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Luc Mercier
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
- UMR 5297, Interdisciplinary Institute for Neurosciences, CNRS Université de Bordeaux, 33076, Bordeaux, France
| | - Maria Jesus Garcia-Leon
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Ignacio Busnelli
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
- Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Angelique Pichot
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
| | - Nicodème Paul
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
| | - Raphaël Carapito
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
| | - Seiamak Bahram
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France
| | - Olivier Lefebvre
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.
- Université de Strasbourg, 67000, Strasbourg, France.
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France.
- Equipe Labellisée Ligue Contre le Cancer, Paris, France.
| | - Jacky G Goetz
- Tumor Biomechanics, INSERM UMR_S1109, CRBS, 67000, Strasbourg, France.
- Université de Strasbourg, 67000, Strasbourg, France.
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), 67000, Strasbourg, France.
- Equipe Labellisée Ligue Contre le Cancer, Paris, France.
| |
Collapse
|
6
|
Gensbittel V, Busnelli I, Osmani N, Goetz JG. Nanoluminal Signaling Shapes Collective Metastasis. Trends Cancer 2020; 7:9-11. [PMID: 33262057 DOI: 10.1016/j.trecan.2020.11.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Accepted: 11/09/2020] [Indexed: 02/03/2023]
Abstract
Clustering of tumor cells is known to grant superior metastatic efficiency compared with single cells. However, the mechanisms involved remain elusive. Reporting in Cell, Wrenn et al. describe how sealed intercellular compartments, nanolumina, are used as growth factor reservoirs within tumor cell clusters to regulate tumor cell proliferation.
Collapse
Affiliation(s)
- Valentin Gensbittel
- INSERM UMR_S1109, Tumor Biomechanics, Strasbourg, France; Université de Strasbourg, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Ignacio Busnelli
- INSERM UMR_S1109, Tumor Biomechanics, Strasbourg, France; Université de Strasbourg, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Naël Osmani
- INSERM UMR_S1109, Tumor Biomechanics, Strasbourg, France; Université de Strasbourg, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.
| | - Jacky G Goetz
- INSERM UMR_S1109, Tumor Biomechanics, Strasbourg, France; Université de Strasbourg, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.
| |
Collapse
|
7
|
Gensbittel V, Kräter M, Harlepp S, Busnelli I, Guck J, Goetz JG. Mechanical Adaptability of Tumor Cells in Metastasis. Dev Cell 2020; 56:164-179. [PMID: 33238151 DOI: 10.1016/j.devcel.2020.10.011] [Citation(s) in RCA: 79] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 09/18/2020] [Accepted: 10/16/2020] [Indexed: 12/12/2022]
Abstract
The most dangerous aspect of cancer lies in metastatic progression. Tumor cells will successfully form life-threatening metastases when they undergo sequential steps along a journey from the primary tumor to distant organs. From a biomechanics standpoint, growth, invasion, intravasation, circulation, arrest/adhesion, and extravasation of tumor cells demand particular cell-mechanical properties in order to survive and complete the metastatic cascade. With metastatic cells usually being softer than their non-malignant counterparts, high deformability for both the cell and its nucleus is thought to offer a significant advantage for metastatic potential. However, it is still unclear whether there is a finely tuned but fixed mechanical state that accommodates all mechanical features required for survival throughout the cascade or whether tumor cells need to dynamically refine their properties and intracellular components at each new step encountered. Here, we review the various mechanical requirements successful cancer cells might need to fulfill along their journey and speculate on the possibility that they dynamically adapt their properties accordingly. The mechanical signature of a successful cancer cell might actually be its ability to adapt to the successive microenvironmental constraints along the different steps of the journey.
Collapse
Affiliation(s)
- Valentin Gensbittel
- INSERM UMR_S1109, Tumor Biomechanics, Strasbourg, France; Université de Strasbourg, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Martin Kräter
- Max Planck Institute for the Science of Light & Max-Planck-Zentrum für Physik und Medizin, Erlangen, Germany
| | - Sébastien Harlepp
- INSERM UMR_S1109, Tumor Biomechanics, Strasbourg, France; Université de Strasbourg, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Ignacio Busnelli
- INSERM UMR_S1109, Tumor Biomechanics, Strasbourg, France; Université de Strasbourg, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Jochen Guck
- Max Planck Institute for the Science of Light & Max-Planck-Zentrum für Physik und Medizin, Erlangen, Germany.
| | - Jacky G Goetz
- INSERM UMR_S1109, Tumor Biomechanics, Strasbourg, France; Université de Strasbourg, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.
| |
Collapse
|
8
|
Follain G, Gensbittel V, Mary B, Lefebvre O, Harlepp S, Hyenne V, Goetz JG. [Influence of fluid mechanics on metastasis formation]. Med Sci (Paris) 2020; 36:872-878. [PMID: 33026329 DOI: 10.1051/medsci/2020158] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Metastases are the main cause of cancer-related deaths. The chain of events leading to their development is called "the metastatic cascade". The biological and biochemical aspects of this process have been well studied but the importance of biomechanical parameters only recently became a focus in the field. Studies have shown the biological fluids (blood, lymph and interstitial fluid) to play a key role in the metastatic cascade. These fluids participate in the transport of circulating tumor cells (CTCs) as well as the factors that they secrete, while at the same time influencing the events of the metastatic cascade through the forces that they generate. The hemodynamic properties and topological constraints of the vascular architecture control the formation of metastatic niches and the metastatic potential of tumor cells. In this review, we discuss the importance of these mechanical forces and highlight the novel questions and research avenues that they open.
Collapse
Affiliation(s)
- Gautier Follain
- Inserm UMR_S1109, 1 place de l'Hôpital, F-67000 Strasbourg, France - Université de Strasbourg, F-67000 Strasbourg, France - Fédération de médecine translationnelle de Strasbourg (FMTS), F-67000 Strasbourg, France - Adresse actuelle : Turku Bioscience Center, University of Turku and Åbo Akademi University, FI-20520, Turku, Finlande
| | - Valentin Gensbittel
- Inserm UMR_S1109, 1 place de l'Hôpital, F-67000 Strasbourg, France - Université de Strasbourg, F-67000 Strasbourg, France - Fédération de médecine translationnelle de Strasbourg (FMTS), F-67000 Strasbourg, France
| | - Benjamin Mary
- Inserm UMR_S1109, 1 place de l'Hôpital, F-67000 Strasbourg, France - Université de Strasbourg, F-67000 Strasbourg, France - Fédération de médecine translationnelle de Strasbourg (FMTS), F-67000 Strasbourg, France
| | - Olivier Lefebvre
- Inserm UMR_S1109, 1 place de l'Hôpital, F-67000 Strasbourg, France - Université de Strasbourg, F-67000 Strasbourg, France - Fédération de médecine translationnelle de Strasbourg (FMTS), F-67000 Strasbourg, France
| | - Sébastien Harlepp
- Inserm UMR_S1109, 1 place de l'Hôpital, F-67000 Strasbourg, France - Université de Strasbourg, F-67000 Strasbourg, France - Fédération de médecine translationnelle de Strasbourg (FMTS), F-67000 Strasbourg, France
| | - Vincent Hyenne
- Inserm UMR_S1109, 1 place de l'Hôpital, F-67000 Strasbourg, France - Université de Strasbourg, F-67000 Strasbourg, France - Fédération de médecine translationnelle de Strasbourg (FMTS), F-67000 Strasbourg, France - CNRS, SNC 5055,
| | - Jacky G Goetz
- Inserm UMR_S1109, 1 place de l'Hôpital, F-67000 Strasbourg, France - Université de Strasbourg, F-67000 Strasbourg, France - Fédération de médecine translationnelle de Strasbourg (FMTS), F-67000 Strasbourg, France
| |
Collapse
|